Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phase.

Leuk Lymphoma · 2014 · PMC4196520 · PMID 24289108

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

A pooled analysis of several single-arm clinical studies found that dasatinib efficacy and safety profiles were similar in Asian and non-Asian patients with CML (all phases), although among patients with CML-CP, Asian patients showed a trend toward higher response rates compared with non-Asians [ 5 ].

also in 53,322 other papers

did not reach statistical significanceno p-value reported

Compared to non-East Asian patients, East Asian patients may have higher exposure to dasatinib based on steady-state AUC, C min and C max trends, but this did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.